Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma

@article{Chuang2007ImmunohistochemicalDO,
  title={Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma},
  author={Ai-Ying Chuang and A. DeMarzo and R. Veltri and Rajni B. Sharma and C. Bieberich and J. Epstein},
  journal={The American Journal of Surgical Pathology},
  year={2007},
  volume={31},
  pages={1246-1255}
}
The histologic distinction between high-grade prostate cancer and infiltrating high-grade urothelial cancer may be difficult, and has significant implications because each disease may be treated very differently (ie, hormone therapy for prostate cancer and chemotherapy for urothelial cancer). Immunohistochemistry of novel and established prostatic and urothelial markers using tissue microarrays (TMAs) were studied. Prostatic markers studied included: prostate-specific antigen (PSA), prostein… Expand
Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma
TLDR
Prostatic and urothelial markers, including PSA, NKX3.1, p63, thrombomodulin, and GATA3 are very useful for differentiating PAC from UC pathologically. Expand
Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma
TLDR
An institutional review of all cases from 2006 to 2012 in which AR IHC had been performed concluded that AR is an important marker as it is best able to distinguish between poorly differentiated urothelial and prostate carcinoma. Expand
Comparison of Immunohistochemistry Expression of CK7, HMWK and PSA in High-Grade Prostatic Adenocarcinoma and Bladder Transitional Cell Carcinoma
TLDR
A panel of immunohistochemical stains can be used to differentiate high-grade prostate adenocarcinoma from urothelial bladder carcinoma in those cases which are challenging to diagnose. Expand
Potential Utiliy of GATA3 and P63 Immunohistochemistry in Differentiating Urothelial Carcinoma from Prostate Adenocarcinoma
TLDR
GATA3 and p63 IHC are sensitive markers for UC and can be used to distinguish prostatic adenocarcinomas from urothelial carcinomas in difficult cases and are also highly specific in excluding high-grade prostatic carcinoma. Expand
Immunohistochemical detection of prostate-specific antigen expression in primary urothelial carcinoma of the urinary bladder.
TLDR
Focal expression of PSA can occasionally be detected in some large, invasive urothelial cancer cells and this phenotypic change should be considered in the differential diagnosis of poorly differentiated carcinoma of the lower urinary tract. Expand
Immunohistochemical Expression of Prostatic Antigens in Adenocarcinoma and Villous Adenoma of the Urinary Bladder
TLDR
The surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenOCarcinoma. Expand
DOUBLE UROGENITAL CANCER: BLADDER AND PROSTATE CANCER - CASE REPORT
TLDR
A diagnosis of cancer in urogenital area should not exclude the existence of other concomitant malignancy, especially in patients in the sixth decade of age, as shown by the case of a smoker male patient, 63-year-old. Expand
The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma
TLDR
Results indicate that PSMA is a highly sensitive and specific immunomarker for the detection of metastatic prostate carcinoma in cytology specimens. Expand
Utility of GATA3 Immunohistochemistry in Differentiating Urothelial Carcinoma From Prostate Adenocarcinoma and Squamous Cell Carcinomas of the Uterine Cervix, Anus, and Lung
TLDR
GATA3 is a sensitive marker for UC, and positive staining in UC is typically nonfocal and moderate or strong in intensity, whereas some cervical and anal SCCs can be GATA3 positive, unlike in UC, staining is more commonly focal and weak. Expand
NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
TLDR
It is demonstrated that PSMA and NKX3.1 are more sensitive markers than PSA for mPCa to the bone following decalcification of bone specimens, and should be used, rather than P SA, as the IHC markers to confirm mPCA to theBone. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Immunophenotype of High-Grade Prostatic Adenocarcinoma and Urothelial Carcinoma
TLDR
A panel of six antibodies is proposed to assist in the distinction of high-grade prostatic adenocarcinoma from high grade urothelial carcinoma: PSA, PSAP, 34βE12, Leu 7, CK 7, and p53. Expand
Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
TLDR
PSA, PAP, UP, and TM are very useful markers in differentiating poorly differentiated UC from PAC when all 4 markers were negative, and CK7 and CK20 appeared of no major use in making the differential diagnosis. Expand
Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores.
  • N. Goldstein
  • Medicine
  • American journal of clinical pathology
  • 2002
TLDR
The prostate can be the primary site of metastatic adenocarcinoma that is nonreactive for PAP and PSA and has CK7 or CK20 reactivity in fewer than 50% of the cells. Expand
Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature
TLDR
A morphological differential diagnosis based selection of immunohistochemical markers is highlighted as a novel approach in the diagnosis of prostate cancer in routine surgical pathology practice. Expand
Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
TLDR
It is concluded that PSMA overexpression is detected in high-grade PIN and is associated with a higher Gleason score of prostate cancer. Expand
Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.
TLDR
The strong inverse correlation between Gleason grade and the PSA content of prostate cancer is confirmed and maps of each grade of cancer from patients with clinical stage T2 cancer confirmed. Expand
Potential Utility of Uroplakin III, Thrombomodulin, High Molecular Weight Cytokeratin, and Cytokeratin 20 in Noninvasive, Invasive, and Metastatic Urothelial (Transitional Cell) Carcinomas
TLDR
A role for an antibody panel that includes UROIII, THR, HMWCK, and CK20 in the diagnosis of urothelial tumors is indicated and the co expression of two of three non-UROIII markers (THR, HMTK, CK20) suggests uroclinical origin but requires clinicopathologic correlation. Expand
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
TLDR
PSMA expression allows the identification of benign and malignant prostatic epithelium and may be a potentially valuable marker in the treatment of patients with prostate cancer. Expand
Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
An optimal immunohistochemical panel to distinguish poorly differentiated prostate (PCa) from urothelial (UCa) carcinoma was selected from a panel consisting of prostate-specific antigen (PSA) andExpand
p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
TLDR
P63 immunohistochemistry represents a potential novel adjuvant method for facilitating the pathologic diagnosis of prostate cancer in prostate needle biopsies and supports the hypothesis that intermediately differentiated cells in the luminal epithelium of PIA are the targets of neoplastic transformation in the prostate. Expand
...
1
2
3
4
...